Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
about
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer TherapyApoptotic pathways as a therapeutic target for colorectal cancer treatmentCD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasApoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategiesTargeting Cell Survival Proteins for Cancer Cell DeathPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Oncogenic MicroRNAs: Key Players in Malignant TransformationThe role of BH3-mimetic drugs in the treatment of pediatric hepatoblastomaResearch advances of arteminAutophagy in malignant transformation and cancer progressionStructural insights into the transcription-independent apoptotic pathway of p53Ion channels and apoptosis in cancerTargeting Mcl-1 for the therapy of cancerHigh-quality NMR structure of human anti-apoptotic protein domain Mcl-1(171-327) for cancer drug designDelivery of RNAi Therapeutics to the Airways-From Bench to BedsideMolecular mechanisms of chemoresistance in gastric cancerIn vitro models of cancer stem cells and clinical applicationsBH3-only proteins: a 20-year stock-takeMicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancerThe copper chelator ATN-224 induces peroxynitrite-dependent cell death in hematological malignanciesAutophagy-Induced Apoptosis in Lung Cancer Cells by a Novel Digitoxin AnalogPanepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancerThe copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphomaStructural and functional similarity between the bacterial type III secretion system needle protein PrgI and the eukaryotic apoptosis Bcl-2 proteinsUpregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cellsApoptosis through Bcl-2/Bax and cleaved caspase up-regulation in melanoma treated by boron neutron capture therapyCurcumin induces apoptosis of upper aerodigestive tract cancer cells by targeting multiple pathwaysMethyl jasmonate: putative mechanisms of action on cancer cells cycle, metabolism, and apoptosisEZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomasDirect Activation of Bax Protein for Cancer TherapyIdentification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens.Loss of VOPP1 overexpression in squamous carcinoma cells induces apoptosis through oxidative cellular injury.Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer.Water-soluble oxoglaucine-Y(III), Dy(III) complexes: in vitro and in vivo anticancer activities by triggering DNA damage, leading to S phase arrest and apoptosis.Antitumor peptides from marine organismsA competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survivalParis polyphylla Suppresses Proliferation and Vasculogenic Mimicry of Human Osteosarcoma Cells and Inhibits Tumor Growth In Vivo.A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors.A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
P2860
Q24337757-366E7541-F214-4215-BE01-B77223865748Q26738304-99442A49-B3A8-4A67-94FF-B53679CB1D95Q26749139-5EF597C8-97BA-41A5-AC24-66F8979EC96BQ26750639-3C9E18F4-A402-4085-94E0-35FC5D87706BQ26765447-B874D319-03F3-46BF-9078-37FFD3A2A56EQ26771601-B58D5D9F-B379-4AA0-BD19-FE2D13E306E5Q26773316-C437CDF3-D2CE-4367-B5A2-594EA8A02A46Q26827928-C170215D-FDC4-4A1E-97D5-C5B1FFD3FB49Q26992299-17736727-5338-4C64-BAB1-AFE36633B951Q27000191-322F4DB9-E40C-4E4C-B3DB-F7A790C40814Q27004001-35850306-FCA2-4E65-A8BA-E727F796AA67Q27005947-BD44241F-7FF7-417E-8860-0A9C8DBC43BCQ27011870-42A59D64-7F21-461B-A481-771E56930BD5Q27683609-E5BF4981-BB13-449D-A3B5-69C351BC9A9FQ28067306-60B3042D-A341-4E5D-BD23-9DC2D7306DC9Q28069259-4EBA55BD-FAB9-4795-96ED-459A5C15247DQ28076101-743A229E-5FEC-4076-B794-89A5B7751902Q28085220-83AEDD50-0D6A-474C-98B2-BAB91B8E5A7CQ28114800-C2B3DF50-5C61-4B0F-BEDE-40421AB9C58CQ28382968-068A2343-6672-46B9-BA20-F51AF64E538FQ28386743-2FE06970-7200-4C00-AEBD-202F2840FB59Q28387216-49E61D1C-58F7-4925-BAD0-59424A1DFA1BQ28389285-8FDD2145-9548-4E58-B838-F568EE2CD371Q28476298-06EA7D2E-586F-46E5-BF8E-57853ECDFD1EQ28484487-5DE66BE5-1BA5-47FA-A479-71741B020DB7Q28488368-9D224EFA-8E88-4E0E-9EB4-3851B60486A5Q28546708-F6ACF34F-10C7-48EC-A466-794E7A23E7E3Q28658683-86920C13-807B-4CA1-8BAD-E57E99F2FA00Q28741454-F4FFEDCF-2C35-4693-94F5-7ED30EDDDF06Q30353924-FAD3A4A3-3793-4F26-B4BD-8B1912956871Q30423722-72E50DF8-000D-4AF0-888A-395F84AF0A48Q30453316-385003DF-6256-4D27-802C-A32F395F74BBQ30499609-4A887C85-7228-422F-A639-BAB3D14AE8E8Q30959736-76EFC225-C4B1-439E-BDF1-F466E2432CE9Q31040702-855CF012-9808-476A-A323-D1CD5B1E49C9Q31100573-00A6C3A4-9322-4824-8831-710A2270B0A9Q32178720-D9AC309A-E015-42BA-9ED7-48859604C41CQ33415717-BF90FD15-BF66-4A6F-B919-D6F2D70D9FB9Q33415855-45ED4164-4CC7-4B85-8DC4-8682824024ADQ33431526-326A35A1-6097-4A66-BC83-CF594D1CF910
P2860
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
@ast
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
@en
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
@nl
type
label
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
@ast
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
@en
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
@nl
prefLabel
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
@ast
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
@en
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
@nl
P2860
P3181
P1476
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy
@en
P2093
C Patrick Reynolds
Min H Kang
P2860
P304
P3181
P356
10.1158/1078-0432.CCR-08-0144
P407
P577
2009-02-01T00:00:00Z